NEWTON, Mass.--(BUSINESS WIRE)--Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on developing and commercializing innovative non- systemic oral protein therapeutics to treat metabolic and orphan diseases, presented successful results from the first Phase 2 trial of ALLN-177 (NCT02289755) at the American Society of Nephrology (ASN) Kidney Week 2015 on Saturday, November 7th. ALLN-177 is currently being developed for the treatment of secondary hyperoxaluria in patients with a history of calcium oxalate kidney stones.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
